Medicare AdvantagePrior AuthMedium impact
Eprontia® (topiramate) oral solution (New)
Humana·Neurology, Family Medicine, Internal Medicine +1 more·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has implemented a new prior authorization policy for Eprontia (topiramate) oral solution effective January 1, 2026. Prior authorization is required for all three indications: migraine prevention (age 12+), epilepsy adjunct therapy (age 2+), and epilepsy monotherapy (age 2+), with specific criteria including previous trial or intolerance to immediate-release topiramate tablets/capsules.
Action Required
Before January 1, 2026: Billing team must update prior authorization systems to require approval for all Eprontia (topiramate oral solution) prescriptions for Medicare Advantage patients. Providers must document previous trial/intolerance to immediate-release topiramate and meet age-specific criteria (12+ for migraine, 2+ for epilepsy). For migraine prevention, also document previous treatment/intolerance to SNRI or tricyclic antidepressants. Claims without prior authorization will be denied.